EGFR-IN-43

EGFR-IN-43 (Compound 17c) is a potent dual-action inhibitor, covalently linking gefitinib with tamoxifen/endoxifen to simultaneously target EGFR and the estrogen receptor. It exhibits single-digit nanomolar EGFR inhibition and retains ER antagonism, demonstrating promising anti-cancer activity in cellular studies for researching combination therapies in resistant cancers.